---
title: "AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295152135.md"
description: "AIM ImmunoTech signed a manufacturing agreement with Sterling Pharma Solutions to produce additional PolyI and Poly C12U batches at Sterling's UK facility. The project, estimated at $1.5 million paid over 12 months, involves transferring test methods for Ampligen polymer precursor production. This output aims to support ongoing and future clinical trials, including a potential Phase 3 study for metastatic pancreatic cancer."
datetime: "2026-08-06T22:24:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295152135.md)
  - [en](https://longbridge.com/en/news/295152135.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295152135.md)
generator: "portal-rs"
---

# AIM ImmunoTech signs manufacturing pact with Sterling Pharma, cost seen at $1.5 million

-   AIM ImmunoTech entered a proposal agreement on July 31, 2026 with Sterling Pharma Solutions to manufacture additional PolyI and Poly C12U batches. \* Work will be carried out at Sterling’s Dudley, UK site, including transfer of associated test methods to support Ampligen polymer precursor production. \* Estimated cost is about $1.5 million, paid over 12 months. \* Output is intended to support ongoing and future clinical trials, including a potential Phase 3 study in metastatic pancreatic cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036408), on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [AIM.US](https://longbridge.com/en/quote/AIM.US.md)
- [AIMID.US](https://longbridge.com/en/quote/AIMID.US.md)
- [AIMI.US](https://longbridge.com/en/quote/AIMI.US.md)

## Related News & Research

- [Why Now On-Demand Conference Spotlights Nine Emerging Biotech And Healthcare Stories](https://longbridge.com/en/news/297400450.md)
- [Alpha Tau completes enrollment in 48-patient IMPACT pancreatic cancer Alpha DaRT pilot study](https://longbridge.com/en/news/297513505.md)
- [Emmaus Life Sciences Announces Agreement for Evaluation of L-glutamine for Pancreatic Cancer | EMMA Stock News](https://longbridge.com/en/news/297525880.md)
- [Innocan Pharma reports Q2 results](https://longbridge.com/en/news/297557245.md)
- [06:05 ETKarmanos Now Offers FDA-Approved Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer](https://longbridge.com/en/news/297497971.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**